Eli Lilly (NYSE: LLY), CRISPR Therapeutics (NASDAQ: CRSP), and Johnson & Johnson (NYSE: JNJ) have all been doing so. Eli Lilly and CRISPR are developing radical new therapies, while Johnson & Johnson is going all-in on using artificial intelligence to bring new therapies to market more quickly. It's hard to see Eli Lilly as a revolutionary stock.
The Zacks Medical sector has modestly outperformed the S&P 500 over the last three months, up more than 7% vs. the general market's 4% gain.
Top-line data from a phase IIb/III study shows that Anave's (AVXL) lead drug exhibited statistical and clinical improvement in cognition and function in patients with early Alzheimer's disease.